- The French court is reportedly investigating Germany-based Merck KGaA (OTC:MKKGY), saying the company provided misleading information regarding its thyroid drug product Levothyrox.
- The ruling did not concern the new formula for the Levothyrox product but how the company provided information when changing from the old to the new formula.
- It is part of criminal proceedings launched in March 2018.
- Reuters reported that Merck has already been condemned in civil litigations for not providing sufficient information when changing the drug's formulas.
- In March, France's highest court confirmed an appeal court ruling ordering Merck to pay €1,000 each to compensate over 3,300 people suffering from thyroid problems after it changed the drug formula in 2017.
- They had said Merck's decision to remove lactose from the drug to make it easier to handle had resulted in side effects such as memory loss, weight gain, and palpitations.
- Merck also confirmed that the Marseille judge had placed the company under court supervision, asking it to deposit €4.3 million and provide a banking guarantee of up to €7 million, which its lawyer said was "totally unjustified."
Loading...
Loading...
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.